Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis

[1]  Brian A. Joughin,et al.  The injury response to DNA damage in live tumor cells promotes antitumor immunity , 2021, Science Signaling.

[2]  L. Domański,et al.  The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage , 2021, International journal of molecular sciences.

[3]  J. Rysz,et al.  Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer , 2021, International journal of molecular sciences.

[4]  E. Felip,et al.  Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  B. Bastani,et al.  Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond , 2020, Cureus.

[6]  C. Porta,et al.  The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? , 2020, Frontiers in Immunology.

[7]  R. Hannan,et al.  Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma , 2020, Journal for ImmunoTherapy of Cancer.

[8]  Christopher T. Chan,et al.  Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes , 2020, Journal for immunotherapy of cancer.

[9]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[10]  Shayan Shirazian,et al.  Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. , 2020, Journal of the American Society of Nephrology : JASN.

[11]  Y. Döring,et al.  Neonatal obstructive nephropathy induces necroptosis and necroinflammation , 2019, Scientific Reports.

[12]  M. Kanbay,et al.  Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non‐small‐cell lung cancer , 2019, Journal of clinical pharmacy and therapeutics.

[13]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Soria,et al.  Renal toxicities associated with pembrolizumab , 2018, Clinical kidney journal.

[15]  E. Gianchecchi,et al.  Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression , 2018, Front. Immunol..

[16]  B. Afşar,et al.  Hyperthermic intraperitonal chemotherapy is an independent risk factor for development of acute kidney injury. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[17]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[18]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[19]  Dana Pe’er,et al.  Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade , 2017, Cell.

[20]  K. Jhaveri,et al.  Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review , 2017, American Journal of Nephrology.

[21]  Ronald D. Vale,et al.  T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition , 2016, Science.

[22]  D. Leaf,et al.  Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. , 2016, Kidney international.

[23]  Axel Hoos,et al.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies , 2016, Nature Reviews Drug Discovery.

[24]  H. Anders,et al.  Necroinflammation in Kidney Disease. , 2016, Journal of the American Society of Nephrology.

[25]  D. Green,et al.  Two independent pathways of regulated necrosis mediate ischemia–reperfusion injury , 2013, Proceedings of the National Academy of Sciences.

[26]  A. Khwaja.  KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[27]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[28]  M. Perazella,et al.  Renal vulnerability to drug toxicity. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[29]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[30]  J. Bluestone,et al.  Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.

[31]  C. Ronco,et al.  Acute renal failure in cancer patients , 2005, Annals of medicine.